» Articles » PMID: 15115918

A 6 Bp Polymorphism in the Thymidylate Synthase Gene Causes Message Instability and is Associated with Decreased Intratumoral TS MRNA Levels

Overview
Specialties Genetics
Pharmacology
Date 2004 Apr 30
PMID 15115918
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A 6 bp deletion polymorphism in the thymidylate synthase (TS) gene was investigated in order to determine its function.

Methods: A luciferase system was used to investigate the function of the 6 bp/1494 polymorphism in vitro. A group of 43 patients with colorectal carcinoma were evaluated for the 6 bp/1494 polymorphism and for intratumoral TS mRNA levels in vivo.

Results: The 3'UTR of TS containing the +6 bp polymorphism resulted in an approximate 35% decrease in luciferase activity and mRNA levels, while the TS-3'UTR bearing the -6 bp deletion resulted in an approximate 70% decrease in luciferase activity and mRNA levels. The TS-3'UTR construct containing the -6 bp/1494 deletion also had a higher rate of message degradation compared to the +6 bp/1494 construct. Individuals homozygous for the insertion (+6 bp/+6 bp) had significantly higher TS mRNA levels compared to individuals that were homozygous for the deletion (-6 bp/-6 bp) (P < 0.007). We determined the frequency of the -6 bp/1494 deletion polymorphism to be 41% in non-Hispanic whites, 26% in Hispanic whites, 52% in African-Americans and 76% in Singapore Chinese.

Conclusions: These results suggest that the -6 bp/1494 deletion polymorphism in the 3'UTR of TS is associated with decreased mRNA stability in vitro and lower intratumoral TS expression in vivo. Further, the 6 bp/1494 polymorphism varies greatly within different ethnic populations and is in linkage disequilibrium with the TS 5' tandem repeat enhancer polymorphism. Taken together, these data suggest that the 6 bp/1494 polymorphism may be a useful screening tool in predicting TS mRNA expression.

Citing Articles

Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment.

Valenzuela G, Contreras H, Marcelain K, Burotto M, Gonzalez-Montero J Int J Mol Sci. 2025; 26(3).

PMID: 39940936 PMC: 11818086. DOI: 10.3390/ijms26031168.


Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients - identification of novel single nucleotide polymorphism: Cross-sectional study.

Mutlak Q, Kasim A, Aljanabi A Medicine (Baltimore). 2024; 103(23):e38448.

PMID: 38847705 PMC: 11155610. DOI: 10.1097/MD.0000000000038448.


The effects of thymidylate synthase 3'UTR genotype on methylation of tumor-specific genes promoter in 22 colorectal cancer patients from southern Iran.

Niknam M, Naghibalhossaini F, Zamani M, Hosseini S, Mokarram P Mol Biol Res Commun. 2024; 13(2):89-102.

PMID: 38504782 PMC: 10946552. DOI: 10.22099/mbrc.2023.48009.1850.


The Association Between Thymidylate Synthase Gene Polymorphisms and the Risk of Ischemic Stroke in Chinese Han Population.

Yu F, Shi L, Wang Q, Xing X, Li Z, Hou L Biochem Genet. 2023; 62(1):468-484.

PMID: 37378701 PMC: 10901929. DOI: 10.1007/s10528-023-10431-8.


Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants.

Raber I, Frazer M, Zerillo J, Asnani A JACC CardioOncol. 2021; 2(2):329-332.

PMID: 34396241 PMC: 8352086. DOI: 10.1016/j.jaccao.2020.04.005.